A new digital PCR–based assay for detecting and monitoring KMT2A rearrangements in acute myeloid leukemia is now available for research use in clinical trials and as a stand-alone kit for global customers. The assay, LeukoStrat® KMT2A + MRD Assay, will soon be offered as a service through regional LabPMM® laboratories.
The assay, according to its manufacturer Invivoscribe®, gives translational researchers and biopharmaceutical partners a critical tool to assess MRD and to evaluate therapeutic responses.
The company reported that the assay is sensitive and precise, resulting in rapid turnaround times. The LeukoStrat assay and software are integrated to provide both initial screening and long-term tracking in one place. This precision makes the assay a critical tool for researchers and biopharmaceutical partners, particularly those developing new treatments like menin-inhibitors, according to a press release by Invivoscribe.
While the assay currently focuses on AML, Invivoscribe plans to expand its utility to include acute lymphocytic leukemia later this year by adding four additional KMT2A rearrangements frequently found in the disease, the company reported.
